Foster City, California–(Newsfile Corp. – November 27, 2023) – MetaNovas, an innovative player in the biopharma and consumer health industry, has been named a winner in the prestigious L'Oréal North Asia Big Bang Beauty Tech Innovation Program. This accolade underscores MetaNovas' unique approach to integrating scientific rigor from pharmaceutical development into the consumer health sphere, especially in developing clinical-grade consumer health products.
As the only company capable of end-to-end development, MetaNovas offers a comprehensive understanding from biological insights to final product creation. This distinct capability has set MetaNovas apart in the industry, especially in understanding consumer markets and applying technology to address consumer health problems.
The L'Oréal North Asia Big Bang Beauty Tech Innovation Program, the first of its kind by the French beauty giant, aims to drive innovation and co-create future beauty solutions across China, Japan, and South Korea. MetaNovas was among the select winners who demonstrated exceptional capabilities in fields such as operations, digital innovation, research, sustainability, generative AI, raw materials, and beauty device development.
MetaNovas' participation in L'Oréal's program highlights their technological prowess in enhancing R&D innovation within the cosmetic industry. Initially focused on drug discovery and developing new therapeutic solutions for clinical problems, MetaNovas has successfully expanded its expertise to the beauty industry. Their technology has notably reduced the traditional months-long R&D process to just a few weeks, significantly accelerating product development and market readiness.
"MetaNovas is not just a company; it's a commitment to pushing the boundaries of what's possible, creating a future where science and technology converge to redefine the landscape of health and wellness," says Lun Yu, Co-Founder of MetaNovas.
The win also grants MetaNovas the opportunity to collaborate further with L'Oréal, join the North Asia Big Bang Entrepreneur Community, and showcase their innovations on strategic regional and global platforms. This recognition at the China International Import Expo (CIIE), attended by over 3,000 businesses from nearly 150 countries, marks a significant milestone for MetaNovas in the global consumer health and beauty tech space.
As MetaNovas looks to the future, their mission remains steadfast: to bring science-backed solutions into the consumer health product sector, enhancing the quality of human life. Their focus on developing products that address everyday health challenges and promote better mental health is at the core of their philosophy.
For more information about MetaNovas and their innovative approaches in the consumer health industry, visit https://www.metanovas.com
MetaNovas stands at the forefront of biopharmaceutical and consumer health innovation, blending its biopharma origins with a commitment to developing clinical-grade products for everyday wellness. Its distinction in the field is highlighted by its recognition at the 2023 IFSCC Congress and inclusion among the 250 Most Promising Early-stage Digital Health Ventures. Central to MetaNovas' innovative edge are four core technology platforms: MetaNLP, which processes millions of scientific documents into accessible data for navigating complex biological domains; MetaKG, a biomedical knowledge graph fostering novel discoveries and product development; MetaOmics, focusing on precision-targeted products based on multi-omics data for specific demographics; and MetaPep, combining deep learning and molecular simulations to design bioactive peptides. These platforms, along with collaborations with leaders like L'Oréal, propel MetaNovas in transforming the consumer health landscape by making scientifically validated products widely available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/188772
Westinghouse’s first customer for its eVinci microreactor—a flagship 5-MWe/13-MWth “nuclear battery”—is poised to be the Saskatchewan Research Council (SRC), Canada’s second-largest research and technology organization. SRC—a Saskatchewan government Treasury Board […]
Do black holes, like dying old soldiers, simply fade away? Do they pop like universe-spawning balloons?
Bill Gates, the seventh richest person in the world, has a well-documented affinity for dividend income. This investment preference is clearly reflected in the staggering $464.5 million he earns annually from his portfolio. Gates’s investment strategy, rooted in picking companies with strong dividend yields, showcases his commitment to steady, long-term income streams. The Bill & Melinda Gates Foundation Trust's most recent 13F filing reveals that a significant portion of this income is generate
He sticks to these four indicators regardless of his strategy. His versatile approach has allowed him to remain profitable in different markets.
(Bloomberg) — Reeling from a bear market last year, beaten-up investors decided to send more than $60 billion to exchange-traded funds focusing on dividends.Most Read from BloombergRussia Downs Drones Over Moscow in Ukrainian Retaliatory StrikeBillions Wiped Out as Stock-Safety Trade on Wall Street MisfiresMusk, Netanyahu Visit Massacre Site Amid Antisemitism FurorTreasuries Extend Blockbuster Rally on Fed Wagers: Markets WrapSodium in Batteries: Shift May Herald Another ShakeupEleven months la
When most people think of Jeff Bezos, they think of Amazon.com Inc. and its origin story: starting in a garage with a loan from his parents. But there’s another, lesser-known part of Bezos’s journey. Before Amazon took off, Bezos made a smart investment that could have made him a billionaire outside of Amazon. In 1998, four years after launching Amazon, Bezos invested in a small search engine startup operating out of a garage in Menlo Park, California. This startup, nurtured by the genius of Lar
Advisors looking at new weight-loss drugs as an investment opportunity should pay attention to a new study based on real-world health records. It finds that patents on Eli Lilly’s drug lose more weight than those on Novo’s Wegovy. The paper by health data company Truveta was posted as a preprint shortly before the Thanksgiving holiday, and has not yet been peer reviewed.
Shares of Pfizer Inc. are hovering around $30 as investors adjust to the company's pursuit of a candidate for a weight loss pill, marking its entry into the competitive obesity drug market. The Street responded critically. JPMorgan Chase & Co analysts called the news a setback for the company. Lotiglipron — the disregarded candidate — was expected to be the stronger contender. Meanwhile, SVB Securities labeled the decision "incrementally negative," according to Yahoo! Finance. Still, Pfizer is p
I’ve had a financial advisor, who is a certified financial planner (CFP), since December of last year. I really find his advice super valuable, but I can't seem to get over the fact that he sold all of my Nvidia stock when he took over as my CFP. I had bought $20,000 worth of Nvidia […] The post Ask an Advisor: My Advisor Sold My Nvidia Stock When I Hired Him, Costing Me $50k in Potential Profits. How Do I Deal With It? appeared first on SmartReads by SmartAsset.
Toyota's chairman, who's long resisted EV hype despite pressure, is feeling vindicated, with hybrid sales surging this year.
Cyber Monday is delivering a deal for CD shoppers, with a freshly unveiled 6% offer you can only snatch up today. It's available to anyone nationwide for a 12-month term.
I am 60 years old, married, with no mortgage. We also have $1.1 million in liquid cash and $880,000 in a 401(k). I will have two pensions, which have not started yet, and my wife will have one pension, all … Continue reading → The post Ask an Advisor: I Am 60 Years Old, Have $1.1M Cash, $880K in a 401(k), Several Pensions and Social Security. Should I Retire Now? appeared first on SmartAsset Blog.
Rates on 30-year mortgages fell another few points Wednesday, dropping the average to within a few points of its two-month low. Rates on most loan types dipped or were flat.
FUTU vs. PLTR: Which Stock Is the Better Value Option?
Gold is showing additional proof of a rally toward all-time highs, one strategist says.
The Kraft Heinz board of directors has approved up to $3 billion in a share repurchase program, the maker of ketchup and mac and cheese announced Monday.
One of Russia's most lucrative oil trade routes since the imposition of Western sanctions over the Ukraine conflict faces a major challenge because of the drawbacks of payment in currency other than dollars, with no short-term solution in sight. For decades, the U.S. dollar has been the currency of international oil trade and efforts to find alternatives have been thwarted by the difficulties of conversion, as well as political obstacles. The problems flared when India – which has become Russia's biggest buyer of seaborne oil since European customers retreated – insisted in July on paying in rupees and the trading activity nearly fell apart, according to three sources familiar with the matter.
Biotech stock Xenon rocketed Monday, after its experimental epilepsy drug unexpectedly showed promise in depression treatment.
I turn 58 this year and am at a loss for what to do or how to plan for my retirement. I only have a small amount of money invested through previous employers, and I'm not sure how to save … Continue reading → The post Ask an Advisor: I'm Way Behind on Retirement Savings. What Do I Do? appeared first on SmartAsset Blog.
Last week, Nvidia Corporation (NASDAQ: NVDA) reported staggering third-quarter results. Despite its reliance on Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM), Nvidia’s Data Center division drove this impressive growth, allowing the company to outshine its competitors, including TSMC, as well as Intel (NASDAQ: INTC), and Advanced Micro Devices, Inc. (NASDAQ: AMD). But, shares slumped upon news that Nvidia is delaying the launch of its new AI chip for China, touted as the most pow